Takeda Acquires US Biologics Manufacturing Facility
Takeda Pharmaceuticals announced the acquisition of a biopharmaceuticals manufacturing plant in Minnesota.
Takeda Pharmaceutical Company Limited announced the acquisition of a Brooklyn Park, Minnesota-based biologics manufacturing facility from Baxalta Inc in a Jan. 6, 2016 press announcement.
Takeda is a Japan-based pharmaceutical company focused on research and development. It is the largest pharmaceutical company in Japan.
According to the company, Takeda intends to use the facility primarily for the manufacture of Entyvio (vedolizumab) and other biologic products. FDA approved Entyvio in May 2014 for the treatment of ulcerative colitis and moderate-to-severe Crohn’s disease.
Terms of the transaction were not disclosed.
Source: Takeda Pharmaceutical Company
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
